Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

195P - A prognostic signature based on two-miRNA and pathological data in early-stage HER2+ breast cancer patients


16 Sep 2021


ePoster Display


Clinical Research;  Translational Research

Tumour Site

Breast Cancer


Anna Adam Artigues


Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687


A. Adam Artigues1, M.Á. Beltrán2, J.A. Carbonell-Asins2, S. Zuñiga3, S. Moragón1, M.T.M. Martinez1, C. Hernando Melia1, O. burgués1, F. Rojo Todo4, J. Albanell Mestres5, A. Lluch-Hernandez1, B. Bermejo1, P. Eroles1, J.M. Cejalvo1

Author affiliations

  • 1 Oncology Department, INCLIVA Biomedical Research Institute, 46010 - Valencia/ES
  • 2 Biostatistics Unit, INCLIVA Biomedical Research Institute, 46010 - Valencia/ES
  • 3 Precision Medicine Unit, INCLIVA Biomedical Research Institute and CIBERONC, 46010 - Valencia/ES
  • 4 Pathological Anatomy, Hospital Universitario Fundación Jiménez Díaz, 28040 - Madrid/ES
  • 5 Cancer Research Program, Hospital del Mar, 08003 - Barcelona/ES

Abstract 195P


In early-stage HER2+ breast cancer (BC), de-escalation of systemic treatment remains a challenge. New biomarkers into risk scoring will help improvement in this field. We aim to develope a prognostic signature based on 2 miRNAs (A, B), quantitative and qualitative clinical variables in HER2+ BC patients.


A retrospective patients’ cohort (n= 45) who received standard treatment for localized disease was selected. We calculated a prognostic signature for disease-free survival (DFS) by principal components analysis combining pathological data (Ki67 and axillary lymph node status) and expression of miRNAs. Multiple DFS prognostic signatures were calculated and goodness of fit was evaluated by Akaike’s Information Criterion to perform Cox model selection. Signature was dichotomized into high risk and low risk using maximally selected Log-Rank statistics by Hothorn and Lausen, as method for optimal cut-off. Target genes were predicted and functional enrichment analysis was performed with KEGG and validated by western blot after miRNA mimics transfection.


MiR-A and B were strongly correlated (r=0.84) and their expression was higher in primary tumor of patients who relapsed (miR-A p= 0.004, miR-B p= 0.018). Our signature was significantly associated with relapse (HR 1.72; CI 95%: 1.24–2.38; p<0.01, AIC=114). Median DFS of the high risk was 44 months while it was not reached in low risk after 67 months of median follow-up (HR 8.39; p=0.005, AIC=111). Significant differences in survival between both groups were found (p< 0.001). This signature was not applicable in other BC subtypes. Functional enrichment analysis returned 55 significant pathways. Interestingly, P53, apoptosis and DNA damage were in the top 5 enriched pathways. Protein expression of predicted targets from these pathways was decreased after miRNA overexpression.


Both miRNA are related to main biological pathways associated to BC. Our prognostic signature identifies patients with early-stage HER2+ BC who might be candidates for de-escalated systemic treatment. This signature was able to classify patients for DFS in high or low risk groups at the moment of BC diagnosis. Further investigations to validate the value of this signature are on-going.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

INCLIVA Biomedical Research Institute.


Spanish Ministry of Economy and Competitiveness and Feder Funds.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.